All In Biotech

Drug Trial Radar · NCT07704645

The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer

A Phase II Clinical Study of Adebelizumab Combined With Other Anti-tumor Treatments as a Perioperative Treatment for Resectable Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Aug 2026

Primary completion

Jun 2028

Study completion Dec 2029

Sponsor

Sponsor type
Industry
First posted
Jul 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, multicenter phase II clinical trial of adebelizumab combined with other anti-tumor therapies in patients with non-small cell lung cancer. The aim of this study was to evaluate the safety, tolerability and efficacy of adebelizumab combined with other anti-tumor therapies in patients with resectable non-small cell lung cancer ( NSCLC )

Conditions

  • Resectable Non-small Cell Lung Cancer

Interventions

  • Adebrelimab Injection combined with SHR-1826 Injection combined with SHR-8068 InjectionDrug

    Adebrelimab Injection combined with SHR-1826 Injection combined with SHR-8068 Injection

  • Adebrelimab Injection combined with HRS-7058 CapsuleDrug

    Adebrelimab Injection combined with HRS-7058 Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathological complete response (pCR) rate: pCR is defined as the absence of any residual tumor at the time of surgical resection.Time frame: All results are expected to be obtained in the last participant three months after surgery.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.